# OptiTROP-Lung05 (NCT06448312)

> A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06448312
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Non-Small Cell Lung Cancer
- Interventions: SKB264; Pembrolizumab
- Enrollment: 406
- Primary outcome: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on OptiTROP-Lung05 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 52
- Podcasts: 6
- YouTube: 2
- Bluesky threads: 2
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=optitrop-lung05-nct06448312

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06448312", "email": "<work email>"}; the inbox owner confirms by the emailed link.